Health IMS: Total U.S. promotional spend by type, 2004. 2005, [http://www.imshealth.com/ims/portal/front/articleC/0,2777,6599_49695992_75406357,00.html]
Brody H: The company we keep: why physicians should refuse to see pharmaceutical representatives. Ann Fam Med. 2005, 3: 82-85. 10.1370/afm.259.
Orlowski JP, Wateska L: The effects of pharmaceutical firm enticements on physician prescribing patterns. There's no such thing as a free lunch. Chest. 1992, 102: 270-273.
Figueiras A, Caamano F, Gestal-Otero JJ: Influence of physician's education, drug information and medical-care settings on the quality of drugs prescribed. Eur J Clin Pharmacol. 2000, 56: 747-753. 10.1007/s002280000217.
Wazana A: Physicians and the pharmaceutical industry: is a gift ever just a gift?. JAMA. 2000, 283: 373-380. 10.1001/jama.283.3.373.
Chew LD, O'Young TS, Hazlet TK, Bradley KA, Maynard C, Lessler DS: A physician survey of the effect of drug sample availability on physicians' behavior. J Gen Intern Med. 2000, 15: 478-483. 10.1046/j.1525-1497.2000.08014.x.
Xu KT, Moloney M, Phillips S: Economics of suboptimal drug use: cost-savings of using JNC-recommended medications for management of uncomplicated essential hypertension. Am J Manag Care. 2003, 9: 529-536.
Siegel D, Lopez J: Trends in antihypertensive drug use in the United States: do the JNC V recommendations affect prescribing? Fifth Joint National Commission on the Detection, Evaluation, and Treatment of High Blood Pressure. JAMA. 1997, 278: 1745-1748. 10.1001/jama.278.21.1745.
Wang TJ, Ausiello JC, Stafford RS: Trends in antihypertensive drug advertising, 1985-1996. Circulation. 1999, 99: 2055-2057.
Zweifler J, Hughes S, Schafer S, Garcia B, Grasser A, Salazar L: Are sample medicines hurting the uninsured?. J Am Board Fam Pract. 2002, 15: 361-366.
Opie LH, Schall R: Evidence-based evaluation of calcium channel blockers for hypertension: equality of mortality and cardiovascular risk relative to conventional therapy. J Am Coll Cardiol. 2002, 39: 315-322. 10.1016/S0735-1097(01)01728-4.
Peay MY, Peay ER: Innovation in high risk drug therapy. Soc Sci Med. 1994, 39: 39-52. 10.1016/0277-9536(94)90164-3.
The Drug Promotion Database. 2002, [http://www.drugpromo.info]
Gonul F: Promotion of prescription drugs and its impact on physicians' choice behavior. Journal of Marketing. 2001, 216: 79-90.
Hodges B: Interactions with the pharmaceutical industry: experiences and attitudes of psychiatry residents, interns and clerks. CMAJ. 1995, 153: 553-559.
Ziegler MG, Lew P, Singer BC: The accuracy of drug information from pharmaceutical sales representatives. JAMA. 1995, 273: 1296-1298. 10.1001/jama.273.16.1296.
Katz D, Caplan AL, Merz JF: All gifts large and small: toward an understanding of the ethics of pharmaceutical industry gift-giving. Am J Bioeth. 2003, 3: 39-46. 10.1162/15265160360706552.
Avorn J, Chren M, Hartley R: Scientific versus commercial sources of influence on the prescribing behavior of physicians. Am J Med. 1982, 73: 4-8. 10.1016/0002-9343(82)90911-1.
Lexchin J: Doctors and detailers: therapeutic education or pharmaceutical promotion?. Int J Health Serv. 1989, 19: 663-679.
Lexchin J: Interactions between physicians and the pharmaceutical industry: what does the literature say?. CMAJ. 1993, 149: 1401-1407.
Lexchin J: What information do physicians receive from pharmaceutical representatives?. Can Fam Physician. 1997, 43: 941-945.
Lexchin J, Holbrook A: Methodologic quality and relevance of references in pharmaceutical advertisements in a Canadian medical journal. CMAJ. 1994, 151: 47-54.
Mapes R: Aspects of British general practitioners' prescribing. Medical Care. 1977, 15: 371-381.
Bower AD, Burkett GL: Family physicians and generic drugs: a study of recognition, information sources, prescribing attitudes, and practices. Journal of Family Practice. 1987, 24: 612-616.
Caudill TS, Lurie N, Rich EC: The influence of pharmaceutical industry advertising on physician prescribing. J Drug Issues. 1992, 22: 331-338.
Becker MH, Stolley PD, Lasagna L, McEvilla JD, Sloane LM: Differential education concerning therapeutics and resultant physician prescribing patterns. Journal of Medical Education. 1972, 47: 118-127.
Stolley PD, Becker MH, Lasagna L, McEvilla JD, Sloane LM: The relationship between physicians characteristics and prescribing appropriateness. Medical Care. 1972, 10: 17-28.
Haayer F: Rational prescribing and sources of information. Soc Sci Med. 1982, 16: 2017-2023. 10.1016/0277-9536(82)90158-7.
Cormack MA, Howells E: Factors linked to the prescribing of benzodiazepines by general practice principals and trainees. Family Practice. 1992, 9: 466-471.
Stross JK: Information sources and clinical decisions. Journal of General Internal Medicine. 1987, 2: 155-159.
Strickland-Hodge B, Jepson MH: Identification and characterization of early and late prescribers in general practice. Journal of the Royal Society of Medicine. 1982, 75: 341-345.
DL S, al : Evidence-Based Medicine: How to practice and teach EBM. 2000, Edinburgh London, Churchill Livingstone, 2nd
SPSS, Inc. 2002, Chicago, Il.
Byrt T, Bishop J, Carlin JB: Bias, prevalence and kappa. J Clin Epidemiol. 1993, 46: 423-429. 10.1016/0895-4356(93)90018-V.
Feinstein AR, Cicchetti DV: High agreement but low kappa: I. The problems of two paradoxes. J Clin Epidemiol. 1990, 43: 543-549. 10.1016/0895-4356(90)90158-L.
RJ L, GC K: The measurement of onserver agreement for categorical data. Biometrics. 1977, 33: 159-174.
Lexchin J, Bero LA, Djulbegovic B, Clark O: Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ. 2003, 326: 1167-1170. 10.1136/bmj.326.7400.1167.
Cooper RJ, Schriger DL: The availability of references and the sponsorship of original research cited in pharmaceutical advertisements. CMAJ. 2005, 172: 487-491.
Djulbegovic B, Lacevic M, Cantor A, Fields KK, Bennett CL, Adams JR, Kuderer NM, Lyman GH: The uncertainty principle and industry-sponsored research. Lancet. 2000, 356: 635-638. 10.1016/S0140-6736(00)02605-2.
Rochon PA, Gurwitz JH, Simms RW, Fortin PR, Felson DT, Minaker KL, Chalmers TC: A study of manufacturer-supported trials of nonsteroidal anti-inflammatory drugs in the treatment of arthritis. Arch Intern Med. 1994, 154: 157-163. 10.1001/archinte.154.2.157.
Moher D, Cook DJ, Jadad AR, Tugwell P, Moher M, Jones A, Pham B, Klassen TP: Assessing the quality of reports of randomised trials: implications for the conduct of meta-analyses. Health Technol Assess. 1999, 3: i-98.
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002, 288: 2981-2997. 10.1001/jama.288.23.2981.